Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Allakos Inc., a clinical stage biotechnology company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases in the United States. The company's lead product candidate is AK006, which in a Phase I clinical trial for the treatment of chronic spontaneous urticaria (CSU) and other indications. The company was incorporated in 2012 and is headquartered in San Carlos, California. more
Time Frame | ALLK | Sector | S&P500 |
---|---|---|---|
1-Week Return | 14.29% | -2.12% | -3% |
1-Month Return | 27.77% | -3.42% | -0.73% |
3-Month Return | 121.4% | -11.13% | 2.87% |
6-Month Return | 16.5% | -5.74% | 7.17% |
1-Year Return | -54.55% | 3.97% | 25.31% |
3-Year Return | -98.53% | 1.05% | 28.38% |
5-Year Return | -98.9% | 34.37% | 81.89% |
10-Year Return | -96.16% | 97.88% | 183.27% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Cost of Revenue | 1.51M | 2.34M | 4.88M | 9.97M | 6.14M | [{"date":"2019-12-31","value":15.12,"profit":true},{"date":"2020-12-31","value":23.45,"profit":true},{"date":"2021-12-31","value":48.92,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":61.56,"profit":true}] |
Gross Profit | (1.51M) | (2.34M) | (4.88M) | (9.97M) | (6.14M) | [{"date":"2019-12-31","value":-150800000,"profit":false},{"date":"2020-12-31","value":-233900000,"profit":false},{"date":"2021-12-31","value":-488000000,"profit":false},{"date":"2022-12-31","value":-997500000,"profit":false},{"date":"2023-12-31","value":-614100000,"profit":false}] |
Gross Margin | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Operating Expenses | 91.42M | 157.06M | 271.48M | 322.43M | 196.06M | [{"date":"2019-12-31","value":28.35,"profit":true},{"date":"2020-12-31","value":48.71,"profit":true},{"date":"2021-12-31","value":84.2,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":60.81,"profit":true}] |
Operating Income | (91.42M) | (157.06M) | (271.48M) | (322.43M) | (196.06M) | [{"date":"2019-12-31","value":-9141800000,"profit":false},{"date":"2020-12-31","value":-15705700000,"profit":false},{"date":"2021-12-31","value":-27147500000,"profit":false},{"date":"2022-12-31","value":-32242900000,"profit":false},{"date":"2023-12-31","value":-19605600000,"profit":false}] |
Total Non-Operating Income/Expense | 12.25M | 7.89M | 1.99M | 6.15M | 21.09M | [{"date":"2019-12-31","value":58.06,"profit":true},{"date":"2020-12-31","value":37.4,"profit":true},{"date":"2021-12-31","value":9.44,"profit":true},{"date":"2022-12-31","value":29.15,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Pre-Tax Income | (85.37M) | (153.48M) | (269.86M) | (319.95M) | (185.70M) | [{"date":"2019-12-31","value":-8537200000,"profit":false},{"date":"2020-12-31","value":-15348000000,"profit":false},{"date":"2021-12-31","value":-26986000000,"profit":false},{"date":"2022-12-31","value":-31995200000,"profit":false},{"date":"2023-12-31","value":-18570100000,"profit":false}] |
Income Taxes | (7.71M) | (5.86M) | (2.69M) | (2.48M) | - | [{"date":"2019-12-31","value":-770900000,"profit":false},{"date":"2020-12-31","value":-585800000,"profit":false},{"date":"2021-12-31","value":-268700000,"profit":false},{"date":"2022-12-31","value":-247700000,"profit":false},{"date":"2023-12-31","value":"-","profit":true}] |
Income After Taxes | (77.66M) | (147.62M) | (267.17M) | (317.48M) | - | [{"date":"2019-12-31","value":-7766300000,"profit":false},{"date":"2020-12-31","value":-14762200000,"profit":false},{"date":"2021-12-31","value":-26717300000,"profit":false},{"date":"2022-12-31","value":-31747500000,"profit":false},{"date":"2023-12-31","value":"-","profit":true}] |
Income From Continuous Operations | (85.37M) | (153.61M) | (270.02M) | (320.08M) | (166.14M) | [{"date":"2019-12-31","value":-8537200000,"profit":false},{"date":"2020-12-31","value":-15360900000,"profit":false},{"date":"2021-12-31","value":-27002100000,"profit":false},{"date":"2022-12-31","value":-32008300000,"profit":false},{"date":"2023-12-31","value":-16613900000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (77.66M) | (147.62M) | (267.17M) | (317.48M) | (185.70M) | [{"date":"2019-12-31","value":-7766300000,"profit":false},{"date":"2020-12-31","value":-14762200000,"profit":false},{"date":"2021-12-31","value":-26717300000,"profit":false},{"date":"2022-12-31","value":-31747500000,"profit":false},{"date":"2023-12-31","value":-18570100000,"profit":false}] |
EPS (Diluted) | (1.89) | (3.09) | (5.00) | (5.53) | (2.13) | [{"date":"2019-12-31","value":-189,"profit":false},{"date":"2020-12-31","value":-309,"profit":false},{"date":"2021-12-31","value":-500,"profit":false},{"date":"2022-12-31","value":-553,"profit":false},{"date":"2023-12-31","value":-213,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
ALLK | |
---|---|
Cash Ratio | 5.80 |
Current Ratio | 6.08 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
ALLK | |
---|---|
ROA (LTM) | -48.75% |
ROE (LTM) | -121.68% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
ALLK | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.42 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.58 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
ALLK | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 0.00 |
P/B | 1.49 |
Price/FCF | NM |
EV/R | 0.00 |
EV/Ebitda | NM |
Allakos Inc (ALLK) share price today is $1.2
Yes, Indians can buy shares of Allakos Inc (ALLK) on Vested. To buy Allakos Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in ALLK stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Allakos Inc (ALLK) via the Vested app. You can start investing in Allakos Inc (ALLK) with a minimum investment of $1.
You can invest in shares of Allakos Inc (ALLK) via Vested in three simple steps:
The 52-week high price of Allakos Inc (ALLK) is $3.36. The 52-week low price of Allakos Inc (ALLK) is $0.54.
The price-to-earnings (P/E) ratio of Allakos Inc (ALLK) is
The price-to-book (P/B) ratio of Allakos Inc (ALLK) is 1.49
The dividend yield of Allakos Inc (ALLK) is 0.00%
The market capitalization of Allakos Inc (ALLK) is $115.25M
The stock symbol (or ticker) of Allakos Inc is ALLK